Sen. Jim Banks (R-Ind.) hopes the Food and Drug Administration will look into the ingredients of active foreign-made medicines that say they contain online weight loss drugs.
In a letter to FDA committee member Sarah Brenner, the bank warned that it was seeing a surge in drugs with foreign-made ingredients that could pose health risks for Americans who purchase online.
“The booming online grey and black markets are flooding the country with imitations contaminated with foreign-made APIs and counterfeit GLP-1s [active pharmaceutical ingredients]and few Americans buy these drugs are aware of the risks they pose,” the bank wrote in TH. Wednesday letter.
“The Food and Drug Administration (FDA) is requesting detailed information about illegal APIs entering the country and potentially harming Americans,” he added.
GLP-1 refers to a formulated glucagon-like peptide 1 agonist drug – an injectable weight loss drug.
The letter's bank said the FDA's Adverse Event Reporting System Database recorded cases of more than 900 health events related to the issue as of late last year. Seventeen of these cases were killed, the bank wrote.
The bank wrote that the incorrect drugs are in the country due to a lack of FDA ratings at the time of the invasion.
“These drugs are formulated that are never approved by the FDA, have inconsistent doses, contain fraudulent insulin with semaglutide, contaminants, or are actually completely different drugs,” the Indiana Senator said.
Anyone selling such drugs must be shut down, he added.
Banks' letter to Brenner asks how the FDA works together with US customs and border security to educate the community about the differences between real and knock-off drugs while preventing counterfeit drugs from entering the US.
Oka reached out to the FDA for comments.
